Alzheimer's Disease R&D Review
25.9K views | +0 today
Follow
 
Scooped by Krishan Maggon
onto Alzheimer's Disease R&D Review
Scoop.it!

Alzheimer's Drug Race: Roche Ramps Up Drug Trial As Rivals Stumble - Huffington Post

My MoinfoAlzheimer's Drug Race: Roche Ramps Up Drug Trial As Rivals StumbleHuffington PostThe failure of rival antibody drugs bapineuzumab, from Pfizer Inc, Johnson & Johnson and Elan Corp , and solanezumab, from Eli Lilly and Co, has dashed hopes...
more...
No comment yet.
Alzheimer's Disease R&D Review
A review of the Solanezumab (Lilly), Gantenerumab (Roche) the 2  beta amyloid monoclonal antibodies  in Phase III trials and other potential targets is provided. The failure of Bapineuzumab in Phase III trials in 2012 puta question mark on the validity of beta amyloid hypothesis. Bapineuzumab is a fully humanized monoclonal antibody which targets beta amyloid protein involved in Alzheimer's Disease. There are 26 million patients in the world, half in Asia and the rest in N America/Europe with AD.
Curated by Krishan Maggon
Your new post is loading...
Your new post is loading...
Scooped by Krishan Maggon
Scoop.it!

Created public version #237 of the knol: "Bapineuzumab (Pfizer, J&J, Elan) Review"

Created public version #237 of the knol: "Bapineuzumab (Pfizer, J&J, Elan) Review" | Alzheimer's Disease R&D Review | Scoop.it
Krishan Maggon published version 237 of a knol titled: "Bapineuzumab (Pfizer, J&J, Elan) Review"...
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Aptuit R&D Hit to lead

Aptuit R&D Hit to lead | Alzheimer's Disease R&D Review | Scoop.it
We are a pharmaceutical services company that delivers early discovery to mid-phase drug development solutions by applying scientific excellence and outstanding service and employing a team of some of the foremost scientific professionals in the industry. These Drug Discovery and Development professionals offer proven experience in key therapeutic areas. They share a legacy of success, having advanced a large number of molecules efficiently, expeditiously and economically, from early discovery through clinical development with low attrition rates.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

[Full text] Palliative care for patients with Parkinson's disease: an interd | JPRLS

[Full text] Palliative care for patients with Parkinson's disease: an interd | JPRLS | Alzheimer's Disease R&D Review | Scoop.it
Palliative care for patients with Parkinson�s disease: an interdisciplinary review and next step model Kimmy G Su,1 Julie H Carter,1 Keiran K Tuck,2 Tony Borcich,3 Linda A Bryans,4 Lisa L Mann,1 Jennifer L Wilhelm,5 Erik K Fromme6 1Department of Neurology, Oregon Health & Science University, 2The Oregon Clinic-Neurology, 3Parkinson�s Resources of Oregon, 4Northwest Clinic for Voice and Swallowing, Oregon Health and Science University, 5Rehabilitation Services, Oregon Health & Science University, 6Palliative Care Section, OHSU Knight Cancer Institute, Portland, OR, USA Abstract: Late stage Parkinson�s and Parkinson-plus patients have increased needs beyond motor symptom management that cannot be fully addressed in a typical neurology clinic visit. Complicating matters are the concurrent increasing emotional and physical demands on caregivers, which, if addressed, further stretch clinic time constraints. The complex and extensive patient and caregiver needs warrant a dedicated clinic to provide the necessary interdisciplinary care. In contrast to a typical model where the neurology clinician refers the patient to various ancillary treatment groups resulting in multiple separate clinic visits, the interdisciplinary model supports direct communication between the different disciplines during the clinic visit, allowing for a more coordinated response that takes into account multiple perspectives. Such an interdisciplinary model has been utilized in neurologic disorders with complex end-stage disease needs, such as amyotrophic lateral sclerosis with notable improvement in quality of life and survival. The Oregon Health & Science University Parkinson Center and Movement Disorders Clinic has developed an interdisciplinary clinic called Next Step composed of neurology clinicians, a physical therapist, a speech pathologist, a social worker, and a nursing coordinator. The clinic focuses on palliative care issues, including complex late stage motor symptoms, nonmotor symptoms, and quality of life goals of both the patient and caregiver(s). This article describes the Next Step clinic structure and processes, while reviewing the literature and incorporating clinical expertise from the perspective of each discipline. Keywords: palliative care, Parkinson�s disease, caregiver burden, interdisciplinary team, late-stage Parkinson�s, quality of life
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

From skin to brain: Stem cells without genetic modification

From skin to brain: Stem cells without genetic modification | Alzheimer's Disease R&D Review | Scoop.it
A discovery, several years in the making, by a University at Buffalo research team has proven that adult skin cells can be converted into neural crest cells (a type of stem cell) without any genetic modification, and tha
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

F1000Research Article: Associative memory cells: Formation, function and perspective.

F1000Research Article: Associative memory cells: Formation, function and perspective. | Alzheimer's Disease R&D Review | Scoop.it
Associative learning and memory are common activities in life, and their cellular infrastructures constitute the basis of cognitive processes. Although neuronal plasticity emerges after memory formation, basic units and their working principles for the storage and retrieval of associated signals remain to be revealed. Current reports indicate that associative memory cells, through their mutual synapse innervations among the co-activated sensory cortices, are recruited to fulfill the integration, storage and retrieval of multiple associated signals, and serve associative thinking and logical reasoning. In this review, we aim to summarize associative memory cells in their formation, features and functional impacts.
Krishan Maggon 's insight:
Wang JH and Cui S. Associative memory cells: Formation, function and perspective [version 1; referees: awaiting peer review]. F1000Research 2017, 6:283 (doi: 10.12688/f1000research.11096.1)
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

New Method Predicts Who Will Respond to Lithium Therapy

New Method Predicts Who Will Respond to Lithium Therapy | Alzheimer's Disease R&D Review | Scoop.it
Neuroscience News has recent neuroscience research articles, brain research news, neurology studies and neuroscience resources for neuroscientists, students, and science fans and is always free to join. Our neuroscience social network has science groups, discussion forums, free books, resources, science videos and more.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Researchers review progress of treating glutamate signalling in depression

Researchers review progress of treating glutamate signalling in depression | Alzheimer's Disease R&D Review | Scoop.it
Major depressive disorder (MDD) impacts 15 million Americans and is the leading cause of disability, yet current treatments possess limited efficacy. Keta
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

S-nitrosylation of UCHL1 induces its structural instability and promotes α-synuclein aggregation

S-nitrosylation of UCHL1 induces its structural instability and promotes α-synuclein aggregation | Alzheimer's Disease R&D Review | Scoop.it
Ubiquitin C-terminal Hydrolase-1 (UCHL1) is a deubiquitinating enzyme, which plays a key role in Parkinson’s disease (PD).
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Inhibikase Awarded $433,000 from The Michael J. Fox Foundation to Advance Development of Kinase Inhibitor Treatment for Parkinson’s Disease | Inhibikase Therapeutics, Inc.

Inhibikase Awarded $433,000 from The Michael J. Fox Foundation to Advance Development of Kinase Inhibitor Treatment for Parkinson’s Disease | Inhibikase Therapeutics, Inc. | Alzheimer's Disease R&D Review | Scoop.it
ATLANTA, March 9, 2017 – Inhibikase Therapeutics, a clinical-stage specialty pharmaceutical company developing kinase inhibitors to treat neurodegenerative
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Robust Identification of Alzheimer’s Disease subtypes based on cortical atrophy patterns

Robust Identification of Alzheimer’s Disease subtypes based on cortical atrophy patterns | Alzheimer's Disease R&D Review | Scoop.it
Accumulating evidence suggests that Alzheimer’s disease (AD) is heterogenous and can be classified into several subtypes.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Stage-specific functions of Semaphorin7A during adult hippocampal neurogenesis rely on distinct receptors

Stage-specific functions of Semaphorin7A during adult hippocampal neurogenesis rely on distinct receptors | Alzheimer's Disease R&D Review | Scoop.it
The functions of semaphorins in the adult brain are poorly understood. Here the authors show that Sema7A carries out stage-specific functions in the adult hippocampus via differential receptor usage; in progenitor cells, Sema7A inhibits proliferation via acting on PlexinC1, whereas in adult-born neurons, it promotes dendrite growth through β1-integrins.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Study gives clues to causes of Motor Neurone Disease and Parkinson's Disease

Study gives clues to causes of Motor Neurone Disease and Parkinson's Disease | Alzheimer's Disease R&D Review | Scoop.it
Scientists at the University of Bath have made further progress to understanding the role of one of the proteins that causes the neurodegenerative disorder Amyotrophic Lateral Sclerosis (ALS) (also known as Motor Neurone Disease), and Parkinson’s Disease.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Researchers discover how neurons tell each other to die under trauma, disease

Researchers discover how neurons tell each other to die under trauma, disease | Alzheimer's Disease R&D Review | Scoop.it
A major contributor to most neurological diseases is the degeneration of a wire-like part of nerve cells called an axon, which electrically transmits info
more...
No comment yet.
Rescooped by Krishan Maggon from Pharma Biotech Industry Review (Krishan Maggon)
Scoop.it!

Inflazome R&D targets Inflammasomes

Inflazome R&D targets Inflammasomes | Alzheimer's Disease R&D Review | Scoop.it

 

Inflammasomes present a new Opportunity to stop harmful inflammation


Our small-molecule drugs – drugs that can be taken by mouth – block inflammasomes very precisely. By carefully targeting solely the inflammasome, our therapies have the potential to stop harmful inflammation while allowing beneficial inflammation and minimizing side effects.

 

 

Krishan Maggon 's insight:
Clinical and scientific data suggests that inflammation causes many of our most challenging medical conditions. By blocking the inflammasome we stop inflammation from progressing and inflammation-related diseases may never even develop.
more...
Krishan Maggon 's curator insight, Today, 3:31 AM
Inflazome is springboarding off an old Pfizer  compound to design a collection of new inflammasome inhibitors...
Scooped by Krishan Maggon
Scoop.it!

Dementia Discovery Fund

Dementia Discovery Fund | Alzheimer's Disease R&D Review | Scoop.it
The Dementia Discovery Fund is a close collaboration between charity, industry and the government, to provide much-needed investment in innovative dementia research
more...
No comment yet.
Rescooped by Krishan Maggon from Pharma Biotech Industry Review (Krishan Maggon)
Scoop.it!

FDA approves Xadago (safinamide, Newron Pharma, Zambon, Meiji Seika) to treat Parkinson’s disease

FDA approves Xadago (safinamide, Newron Pharma, Zambon, Meiji Seika) to treat Parkinson’s disease | Alzheimer's Disease R&D Review | Scoop.it

The U.S. Food and Drug Administration today approved Xadago (safinamide) tablets as an add-on treatment for patients with Parkinson’s disease who are currently taking levodopa/carbidopa and experiencing “off” episodes. An “off” episode is a time when a patient’s medications are not working well, causing an increase in Parkinson’s symptoms, such as tremor and difficulty walking.


An estimated 50,000 Americans are diagnosed with Parkinson’s disease each year, according to the National Institutes of Health, and about one million Americans have the condition.


The efficacy of Xadago in treating Parkinson’s disease was shown in a clinical trial of 645 participants who were also taking levodopa and were experiencing “off” time. Those receiving Xadago experienced more beneficial “on” time, a time when Parkinson’s symptoms are reduced, without troublesome uncontrolled involuntary movement (dyskinesia), compared to those receiving a placebo. The increase in “on” time was accompanied by a reduction in “off” time and better scores on a measure of motor function assessed during “on” time than before treatment. 


 In another clinical trial of 549 participants, the participants adding Xadago to their levodopa treatment had more “on” time without troublesome uncontrolled involuntary movement compared to those taking a placebo, and also had better scores on a measure of motor function assessed during “on” time than before treatment.


The most common adverse reactions observed in patients taking Xadago were uncontrolled involuntary movement, falls, nausea, and trouble sleeping or falling asleep (insomnia). Serious, but less common, risks include the following: exacerbated high blood pressure (hypertension); serotonin syndrome when used with MAOIs, antidepressants, or opioid drugs; falling asleep during activities of daily living; hallucinations and psychotic behavior; problems with impulse control/compulsive behaviors; withdrawal-emergent hyperpyrexia (fever) and confusion; and retinal pathology.

Krishan Maggon 's insight:
Safinamide is an oral, once a day adjunctive therapy for any stage of Parkinson's disease (PD). It is a unique molecule with a novel dual mechanism of action based on the enhancement of the dopaminergic function (through potent reversible inhibition of MAO-B and of dopamine uptake) and inhibition of the excessive release of glutamate. 

Safinamide is partnered with Meiji Seika Pharma Co., Ltd., a subsidiary of the Meiji Holdings Co., Ltd., in Japan and key Asian territories and with Zambon Group in all other markets, including the US and Europe. 

 In November 2015 Swissmedic approves Xadago® for use in Parkinson’s disease 

 This is the first New Chemical Entity (NCE) in 10 years to receive a Marketing Authorization from the EU Commission for the treatment of Parkinson’s disease and Newron believes it could offer significant improvement to the quality of life of those living with this condition. 

 In July, Newron received a refusal to file (RTF) letter from the US FDA for the use of Xadago® (safinamide) as add-on therapy for patients with Parkinson’s disease. The RTF letter did not relate to the acceptability of the clinical data, and no judgment was made on the efficacy or safety of Xadago® (safinamide). Newron has since then worked closely with the FDA to resolve the organization and navigation problems with the application and has resubmitted the New Drug Application (NDA) to the FDA in December 2014. It is with great satisfaction that the Company has announced on March 2, 2015 the acceptance for filing of the NDA by the FDA.
more...
Krishan Maggon 's curator insight, March 24, 3:24 AM
Safinamide is an oral, once a day adjunctive therapy for any stage of Parkinson's disease (PD). It is a unique molecule with a novel dual mechanism of action based on the enhancement of the dopaminergic function (through potent reversible inhibition of MAO-B and of dopamine uptake) and inhibition of the excessive release of glutamate.
Safinamide is partnered with Meiji Seika Pharma Co., Ltd., a subsidiary of the Meiji Holdings Co., Ltd., in Japan and key Asian territories and with Zambon Group in all other markets, including the US and Europe.

In November 2015 Swissmedic approves Xadago® for use in Parkinson’s disease 

 This is the first New Chemical Entity (NCE) in 10 years to receive a Marketing Authorization from the EU Commission for the treatment of Parkinson’s disease and Newron believes it could offer significant improvement to the quality of life of those living with this condition. 

 In July, Newron received a refusal to file (RTF) letter from the US FDA for the use of Xadago® (safinamide) as add-on therapy for patients with Parkinson’s disease. The RTF letter did not relate to the acceptability of the clinical data, and no judgment was made on the efficacy or safety of Xadago® (safinamide). Newron has since then worked closely with the FDA to resolve the organization and navigation problems with the application and has resubmitted the New Drug Application (NDA) to the FDA in December 2014. It is with great satisfaction that the Company has announced on March 2, 2015 the acceptance for filing of the NDA by the FDA.
Scooped by Krishan Maggon
Scoop.it!

Mechanisms that Synergistically Regulate η-Secretase Processing of APP and Aη-α Protein Levels: Relevance to Pathogenesis and Treatment of Alzheimer’s Disease - Joseph Ward - Discovery Medicine

Mechanisms that Synergistically Regulate η-Secretase Processing of APP and Aη-α Protein Levels: Relevance to Pathogenesis and Treatment of Alzheimer’s Disease - Joseph Ward - Discovery Medicine | Alzheimer's Disease R&D Review | Scoop.it
The pathophysiology of Alzheimer's disease (AD) is characterized by the formation of cerebral β-amyloid plaque from a small peptide amyloid-β (Aβ). Aβ is generated from the canonical amyloid-β precursor protein (APP) proteolysis pathway through β- and γ-secretase. Decreasing Aβ levels .
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Amyloidosis - NHS Choices

Amyloidosis - NHS Choices | Alzheimer's Disease R&D Review | Scoop.it
Amyloidosis is a group of rare but serious conditions caused by deposits of abnormal protein, called amyloid, in tissues and organs throughout the body.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Phenotypic Screening Identifies Modulators of Amyloid Precursor Protein Processing in Human Stem Cell Models of Alzheimer’s Disease

Phenotypic Screening Identifies Modulators of Amyloid Precursor Protein Processing in Human Stem Cell Models of Alzheimer’s Disease | Alzheimer's Disease R&D Review | Scoop.it
Summary Human stem cell models have the potential to provide platforms for phenotypic screens to identify candidate treatments and cellular pathways involved in the pathogenesis of neurodegenerative disorders. Amyloid precursor protein (APP) processing and the accumulation of APP-derived amyloid β (Aβ) peptides are key processes in Alzheimer's disease (AD). We designed a phenotypic small-molecule screen to identify modulators of APP processing in trisomy 21/Down syndrome neurons, a complex genetic model of AD. We identified the avermectins, commonly used as anthelmintics, as compounds that increase the relative production of short Aβ peptides at the expense of longer, potentially more toxic peptides. Further studies demonstrated that this effect is not due to an interaction with the core γ-secretase responsible for Aβ production. This study demonstrates the feasibility of phenotypic drug screening in human stem cell models of Alzheimer-type dementia, and points to possibilities for indirectly modulating APP processing, independently of γ-secretase modulation.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Scientists Have Unraveled the Mystery of How Brain Damage is Repaired

Scientists Have Unraveled the Mystery of How Brain Damage is Repaired | Alzheimer's Disease R&D Review | Scoop.it
Scientists from the Queen’s University in Belfast have discovered that brain repair is facilitated by specific cells from the immune system. This fundamental breakthrough could revolutionize the treatment of Multiple Sclerosis (MS) and other debilitating neurological disorders. The research was led by Dr Denise Fitzgerald and Dr Yvonne Dombrowski, both from the Wellcome Wolfson Institute …
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

NEURODEGENERATIVE DISEASE
A chimeric approach

NEURODEGENERATIVE DISEASE<br/>A chimeric approach | Alzheimer's Disease R&D Review | Scoop.it
It has proved difficult to recapitulate the neuronal loss that is observed in Alzheimer disease (AD) in rodent models of the disorder. In a new study, however, De Strooper, Vanderhaeghen and colleagues generated a chimeric model of AD in which human neurons were transplanted into an AD mouse model and…
Krishan Maggon 's insight:
Darran Yates 
Nature Reviews Neuroscience 18, 193 (2017) doi:10.1038/nrn.2017.38 Published online 17 March 2017
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

A protein puzzle: Untangling the mysterious condition of amyloidosis

Shraddha Chakradhar

A protein puzzle: Untangling the mysterious condition of amyloidosis<br/><br/>Shraddha Chakradhar | Alzheimer's Disease R&D Review | Scoop.it
Empty description
Krishan Maggon 's insight:
A protein puzzle: Untangling the mysterious condition of amyloidosis 
 Shraddha Chakradhar 
Nature Medicine 23, 266–269 (2017) doi:10.1038/nm0317-266 Published online 07 March 2017
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

A novel human–mouse chimaeric model of Alzheimer disease

A novel human–mouse chimaeric model of Alzheimer disease | Alzheimer's Disease R&D Review | Scoop.it
Alzheimer disease (AD)-like amyloid pathology has been modelled with some success in transgenic rodents, but these models fail to recapitulate some of the key features of AD, such as neurodegeneration and tau pathology. In new research reported in Neuron, Bart De Strooper, Pierre Vanderhaeghen and colleagues have attempted to address…
Krishan Maggon 's insight:
Nature Reviews Neurology (2017) doi:10.1038/nrneurol.2017.37 Published online 10 March 2017
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

RAMP CNS Drug Innovation Engine | Inhibikase Therapeutics

RAMP CNS Drug Innovation Engine | Inhibikase Therapeutics | Alzheimer's Disease R&D Review | Scoop.it

Our RAMP (Re-engineering Approach with Metabolism Preserved) drug innovation engine enables us to design and develop novel small-molecule product candidates


Using this approach, Inhibikase is advancing a new class of small-molecule CNS drug candidates that target specific protein kinases in the CNS with dramatically enhanced potency and improved safety profiles that may be administered chronically and systemically to patients with infectious or neurodegenerative CNS diseases.

more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

NeuroLogica Blog » Alzheimer’s and Stem Cells

NeuroLogica Blog » Alzheimer’s and Stem Cells | Alzheimer's Disease R&D Review | Scoop.it
A recent article in The Mercury News reports on the work of a neurosurgeon who is injecting fat-derived stem cells into the brains of Alzheimer's patients
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Autophagy and Microglia: Novel Partners in Neurodegeneration and Aging

Autophagy and Microglia: Novel Partners in Neurodegeneration and Aging | Alzheimer's Disease R&D Review | Scoop.it
Autophagy is emerging as a core regulator of Central Nervous System (CNS) aging and neurodegeneration. In the brain, it has mostly been studied in neurons, where the delivery of toxic molecules and organelles to the lysosome by autophagy is crucial for neuronal health and survival. However, we propose that the (dys)regulation of autophagy in microglia also affects innate immune functions such as phagocytosis and inflammation, which in turn contribute to the pathophysiology of aging and neurodegenerative diseases. Herein, we first describe the basic concepts of autophagy and its regulation, discuss key aspects for its accurate monitoring at the experimental level, and summarize the evidence linking autophagy impairment to CNS senescence and disease. We focus on acute, chronic, and autoimmunity-mediated neurodegeneration, including ischemia/stroke, Alzheimer’s, Parkinson’s, and Huntington’s diseases, and multiple sclerosis. Next, we describe the actual and potential impact of autophagy on microglial phagocytic and inflammatory function. Thus, we provide evidence of how autophagy may affect microglial phagocytosis of apoptotic cells, amyloid-β, synaptic material, and myelin debris, and regulate the progression of age-associated neurodegenerative diseases. We also discuss data linking autophagy to the regulation of the microglial inflammatory phenotype, which is known to contribute to age-related brain dysfunction. Overall, we update the current knowledge of autophagy and microglia, and highlight as yet unexplored mechanisms whereby autophagy in microglia may contribute to CNS disease and senescence.
more...
No comment yet.